Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.

Meissner Y, Richter A, Manger B, Tony HP, Wilden E, Listing J, Zink A, Strangfeld A.

Ann Rheum Dis. 2017 Sep;76(9):1583-1590. doi: 10.1136/annrheumdis-2017-211209. Epub 2017 May 8.

2.

[How frequent are poor prognostic markers in rheumatoid arthritis? : An estimate based on three epidemiologic cohorts].

Albrecht K, Richter A, Meissner Y, Huscher D, Baganz L, Thiele K, Schneider M, Strangfeld A, Zink A.

Z Rheumatol. 2017 Jun;76(5):434-442. doi: 10.1007/s00393-017-0306-4. German.

PMID:
28429118
3.

Primary and secondary patient data in contrast: the use of observational studies like RABBIT.

Richter A, Meißner Y, Strangfeld A, Zink A.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S79-S86. Epub 2016 Oct 19. Review.

4.

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.

Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A.

Arthritis Res Ther. 2016 Aug 5;18(1):183. doi: 10.1186/s13075-016-1077-z.

5.

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J.

Ann Rheum Dis. 2017 Mar;76(3):504-510. doi: 10.1136/annrheumdis-2016-209773. Epub 2016 Jul 12.

6.

Alternative drug delivery approaches for the therapy of inflammatory bowel disease.

Meissner Y, Lamprecht A.

J Pharm Sci. 2008 Aug;97(8):2878-91. Review.

PMID:
17948914
7.

Epithelial heparin delivery via microspheres mitigates experimental colitis in mice.

Pellequer Y, Meissner Y, Ubrich N, Lamprecht A.

J Pharmacol Exp Ther. 2007 May;321(2):726-33. Epub 2007 Feb 22.

PMID:
17322027
8.

Low molecular weight heparin loaded pH-sensitive microparticles.

Meissner Y, Ubrich N, El Ghazouani F, Maincent P, Lamprecht A.

Int J Pharm. 2007 Apr 20;335(1-2):147-53. Epub 2006 Nov 10.

PMID:
17150317
9.

Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery.

Meissner Y, Pellequer Y, Lamprecht A.

Int J Pharm. 2006 Jun 19;316(1-2):138-43. Epub 2006 May 3.

PMID:
16675176

Supplemental Content

Loading ...
Support Center